What Happened

Scientists led by Professor Feng Zhang at MIT and the Broad Institute have created an innovative solution to one of aging’s most challenging problems: the decline of immune function. Their approach bypasses the thymus gland, which normally produces and trains T cells but shrinks dramatically with age, by converting liver cells into temporary producers of crucial immune signals.

The research team identified three key molecular factors that the thymus normally uses to promote T-cell maturation and diversity. They encoded these factors into messenger RNA (mRNA) sequences and packaged them into lipid nanoparticles—the same delivery technology used in COVID-19 vaccines. When injected into the bloodstream, these particles specifically target the liver, where hepatocytes (the liver’s main cells) take up the mRNA and begin manufacturing the encoded proteins.

In laboratory tests with aged mice, the treatment produced remarkable results. The animals showed significantly larger and more diverse T-cell populations when vaccinated, and they responded much better to cancer immunotherapy treatments compared to untreated aged mice. The findings were published in the journal Nature.

Why It Matters

This breakthrough addresses a fundamental challenge of human aging that affects virtually everyone. As people age, their thymus gland progressively shrinks in a process called thymic involution, which begins surprisingly early—often in the teenage years—and accelerates throughout life. By age 60, most people have lost 90% of their thymic function.

The consequences are profound: older adults have weaker responses to vaccines, higher susceptibility to infections, and reduced ability to fight cancer. This immune decline, called immunosenescence, is a major contributor to age-related disease and mortality. Current approaches to boost immune function in older adults, such as adjuvanted vaccines, provide only modest improvements.

The MIT approach represents a paradigm shift by creating an entirely new source of immune-stimulating signals outside the thymus. Unlike previous attempts to regenerate the thymus itself, this liver-based system offers several advantages: the liver is large, accessible, and naturally equipped to produce and secrete proteins into the bloodstream.

Background

The thymus has long been recognized as crucial for immune function, but its early decline made it a challenging target for intervention. Located behind the breastbone, this small organ serves as a ‘boot camp’ for T cells, teaching them to distinguish between the body’s own tissues and foreign threats while promoting their diversification into specialized subtypes.

Previous research efforts focused on thymus regeneration using stem cells, growth factors, or surgical approaches, but these strategies proved difficult to implement safely and effectively in humans. The complexity of recreating the thymus’s specialized microenvironment posed significant technical challenges.

The current breakthrough builds on recent advances in mRNA technology, which gained widespread attention during the COVID-19 pandemic. The researchers leveraged the liver’s natural role as a protein factory—hepatocytes normally produce many of the body’s circulating proteins—making it an ideal target for temporary reprogramming.

The specific molecular factors targeted in this study represent years of research into thymic biology. By identifying the minimal set of signals needed to promote T-cell function, the team created a streamlined approach that avoids the complexity of recreating the entire thymic environment.

What’s Next

While the mouse studies show promising results, significant steps remain before human applications become reality. The researchers must first conduct safety studies to ensure the liver-targeted approach doesn’t cause adverse effects or interfere with the organ’s normal functions. They’ll also need to optimize dosing, timing, and duration of treatment.

Clinical trials will likely begin with older adults who have severely compromised immune systems, potentially including cancer patients or those with immunodeficiencies. If successful, the treatment could eventually be developed as a preventive measure for healthy aging adults.

The broader implications extend beyond individual treatment. If this approach proves effective in humans, it could transform how we think about aging and immune function. Rather than accepting immune decline as inevitable, we might be able to maintain robust immune systems throughout life.

Professor Zhang expressed optimism about the potential impact: “Hopefully we can help people stay free of disease for a longer span of their life.” The research also opens new possibilities for using the liver as a programmable organ for producing therapeutic proteins, potentially addressing other age-related conditions.